bioMérieux is a global leader in the field of in vitro diagnostics, developing solutions that empower healthcare professionals to detect and diagnose infectious diseases, cancers and various other medical conditions. The company’s offerings span automated and semi-automated instruments, reagent kits, software and digital applications designed to streamline laboratory workflows and deliver accurate results rapidly. With a strong emphasis on patient safety and public health, bioMérieux’s diagnostic systems are widely used in hospitals, private laboratories and point‐of‐care settings around the world.
The company’s core portfolio is organized around microbiology, immunoassays, molecular biology and industrial microbiology. In microbiology, bioMérieux provides blood culture systems, identification and antimicrobial susceptibility testing solutions. Its immunoassay lines, such as VIDAS® and miniVIDAS®, offer rapid, reliable detection of biomarkers in human samples, while the BioFire® FilmArray® molecular system supports syndromic testing panels for respiratory, gastrointestinal and central nervous system infections. Additionally, bioMérieux serves the food, pharmaceutical and cosmetic industries with microbial monitoring and quality control tools designed to ensure product safety.
With direct operations in over 40 countries and products distributed in more than 150 territories, bioMérieux maintains a robust global footprint. The company’s international network includes regional hubs in Europe, North America, Asia-Pacific, Latin America, Africa and the Middle East, supported by local manufacturing sites, research centers and technical support teams. This widespread presence enables rapid response to emerging health threats and close partnerships with public health authorities and private sector customers alike.
Founded in 1963 by Dr. Alain Mérieux, bioMérieux has remained a family-led enterprise committed to innovation and quality. Under the leadership of CEO Alexandre Mérieux, the company continues to invest heavily in research and development, collaborating with academic institutions, biotechnology firms and healthcare organizations to address unmet diagnostic needs. By integrating digital technologies and artificial intelligence into its product offerings, bioMérieux aims to enhance decision‐making in clinical and industrial settings and contribute to improved patient outcomes worldwide.
AI Generated. May Contain Errors.
Free BMXMF Stock Alerts